JPM vs LIFE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
With a strong Piotroski F-Score of 7/9 and an intrinsic value estimate of $33.63, LIFE presents a compelling growth-at-a-reasonable-price (GARP) opportunity. The company has successfully pivoted from a long history of losses to significant profitability, evidenced by a 161.6% YoY earnings growth and a low forward P/E of 7.14. While technical trends remain bearish and book value is negative, the fundamental trajectory and low debt levels suggest a strong recovery phase.
Compare Another Pair
Related Comparisons
JPM vs LIFE: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Ethos Technologies Inc. (LIFE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.